Opin vísindi

Fletta eftir höfundi "Pavelka, Karel"

Fletta eftir höfundi "Pavelka, Karel"

Röðun: Raða: Niðurstöður:

  • Icon
    Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration 
    Michelsen, Brigitte; Lindström, Ulf; Codreanu, Catalin; Ciurea, Adrian; Zavada, Jakub; Loft, Anne Gitte; Pombo-Suarez, Manuel; Onen, Fatos; Kvien, Tore K; Rotar, Ziga; Santos, Maria Jose; Iannone, Florenzo; Hokkanen, Anna-Mari; Gudbjornsson, Bjorn; Askling, Johan; Ionescu, Ruxandra; Nissen, Michael J; Pavelka, Karel; Sanchez-Piedra, Carlos; Akar, Servet; Sexton, Joseph; Tomsic, Matija; Santos, Helena; Sebastiani, Marco; Österlund, Jenny; Geirsson, Arni Jon; Macfarlane, Gary; van der Horst-Bruinsma, Irene; Georgiadis, Stylianos; Brahe, Cecilie Heegaard; Ørnbjerg, Lykke Midtbøll; Hetland, Merete Lund; Østergaard, Mikkel (BMJ, 2020-09-01)
    OBJECTIVES: To explore 6-month and 12-month secukinumab effectiveness in patients with axial spondyloarthritis (axSpA) overall, as well as across (1) number of previous biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), (2) ...
  • Icon
    Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors : Data from the EuroSpA collaboration 
    Ørnbjerg, Lykke Midtbøll; Linde, Louise; Georgiadis, Stylianos; Horskjær Rasmussen, Simon; Lindström, Ulf; Askling, Johan; Michelsen, Brigitte; Di Giuseppe, Daniela; Wallman, Johan K.; Pavelka, Karel; Závada, Jakub; Nissen, Michael J; Jones, Gareth T.; Relas, Heikki; Pirilä, Laura; Tomšič, Matija; Rotar, Ziga; Geirsson, Árni Jón; Guðbjörnsson, Björn; Kristianslund, Eirik K.; van sder Horst-Bruinsma, Irene; Loft, Anne Gitte; Laas, Karin; Iannone, Florenzo; Corrado, Addolorata; Ciurea, Adrian; Santos, Maria José; Santos, Helena; Codreanu, Catalin; Akkoc, Nurullah; Gunduz, Ozgul S.; Glintborg, Bente; Østergaard, Mikkel; Lund Hetland, Merete (2022-10-01)
    Objectives: In patients with axial spondyloarthritis (axSpA) initiating their first tumor necrosis factor alpha-inhibitor (TNFi), we aimed to identify common baseline predictors of Ankylosing Spondylitis Disease Activity Score (ASDAS-CRP) inactive ...
  • Icon
    Sex differences in the effectiveness of first-line tumour necrosis factor inhibitors in axial spondyloarthritis : Results from the EuroSpA Research Collaboration Network 
    Hellamand, Pasoon; Van De Sande, Marleen; Ørnbjerg, Lykke Midtbøll; Klausch, Thomas; Nurmohamed, Michael T.; Van Vollenhoven, Ronald F.; Nordström, Dan; Hokkanen, Anna Mari; Santos, Maria Jose; Vieira-Sousa, Elsa; Loft, Anne G.; Glintborg, Bente; Hetland, Merete Lund; Lindström, Ulf; Wallman, Johan K.; Michelsen, Brigitte; Klami Kristianslund, Eirik; Ciurea, Adrian; Nissen, Michael S.; Codreanu, Catalin; Mogosan, Corina; Macfarlane, Gary J.; Rotariu, Ovidiu; Rotar, Ziga; Tomšič, Matija; Castrejon, Isabel; Otero-Varela, Lucia; Guðbjörnsson, Björn; Geirsson, Árni Jón; Vencovský, Ji; Pavelka, Karel; Gulle, Semih; Zengin, Berrin; Iannone, Florenzo; Foti, Rosario; Ostergaard, Mikkel; Van Der Horst-Bruinsma, Irene (2023-12-12)
    Objective Evidence indicates reduced treatment effectiveness of TNFi in women with axial spondyloarthritis (axSpA) compared with men. We aimed to investigate sex differences in treatment response and retention rates over 24 months of follow-up in axSpA ...